Navigation Links
PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022
Date:11/21/2013

London (PRWEB) November 21, 2013

PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

France has established specialized AD facilities that have made diagnosis much easier in the rural areas of the country. Moreover, accessibility to affordable medications in France is among the highest of the EU countries. However, there is an widespread notion among family physicians in the EU that referral of an AD patient to specialists is sometimes not in the best interest of their patient, which prevents patients from proceeding along the usual pathway to the most effective management.

Scope

-Overview of Alzheimer’s Disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for the top drugs in France from 2012-2022.
-Analysis of the impact of key events as well the drivers and restraints affecting France Alzheimer’s Disease market.

Reasons to buy

-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for Alzheimer’s Disease
-Effectively plan your M&A and partn
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. PharmaPoint: Dry Eye Syndrome - Current and Future Players
2. PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
3. PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022
4. PharmaPoint: Alzheimer’s Disease - India Drug Forecast and Market Analysis to 2022
5. PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022
6. PharmaPoint: Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022
7. PharmaPoint: Chronic Heart Failure - US Drug Forecast and Market Analysis to 2022
8. PharmaPoint: Alzheimer’s Disease - US Drug Forecast and Market Analysis to 2022
9. PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022
10. PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players
11. PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... Florida (PRWEB) March 02, 2015 ... their services and manage their practices compliantly ... an integrated all-inclusive solution. The interoperability ... program and a medical practice management system ... and long-term financial sustainability. A referral management ...
(Date:3/1/2015)... Orion, Metamora, Michigan (PRWEB) March 01, 2015 ... is approved to treat Overactive Bladder (OAB) symptoms, such as ... in adults when another type of medication (anticholinergic) does not ... a different treatment option that takes another approach to targeting ... , BOTOX® works on the nerves and bladder muscle, blocking ...
(Date:3/1/2015)... York (PRWEB) March 01, 2015 ... lawsuit (( http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) scheduled to go to ... must prepare a witness to provide testimony regarding ... the development of the Profemur device, Bernstein Liebhard ... U.S. District Court, Northern District of Iowa on ...
(Date:3/1/2015)... 2015 ERISAPros is pleased ... Roddy to the professional staff of its Compliance Department. ... The Ohio State University-Mortiz College of Law. Prior to ... working with several Fortune 500 companies as well as ... corporate benefits. Her experiences range from benefit plan design, ...
(Date:2/28/2015)... The MCA Youth Empowerment Conference aims to bridge ... gears towards the goal for a better future for ... in smaller groups will be held after the conference ... Entrepreneurship, Healthcare, Social and Volunteerism, Women and Youth Empowerment, ... , Young adults aged between 18-30 years that ...
Breaking Medicine News(10 mins):Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 4Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4
... School of Medicine and the Case Comprehensive Cancer ... a highly competitive $5.4 million grant to study ... This five-year award from the National Cancer Institute ... (BETRNet), which consists of multiple centers collaborating to ...
... prescription medications, including antidepressants, antihistamines, bronchodilators, anticholinergics, sympathomimetics, ... urinary tract symptoms among men according to a ... of Internal Medicine . This study demonstrates ... prescription drugs and LUTS among men enrolled in ...
... partnership with the American Society for Radiation Oncology (ASTRO), ... recognized 39 educators with the 2011 Educator of the ... the Year Award to recognize outstanding teachers and mentors ... programs were given the opportunity to select one faculty ...
... medical (CAM) treatments such as herbal supplements have become ... patients and those with chronic pain. However, many of ... effects when combined with medications prescribed during and after ... Journal of the American Academy of Orthopaedic Surgeons ...
... 11, 2011 Previous studies have documented that women ... than women without disabilities. A new study published online ... is the first population-based investigation to examine sexual ... men with disabilities are more than four times more ...
... woman with Restless Legs Syndrome, you may have a higher ... reported in Hypertension: Journal of the American Heart Association ... disorder characterized by intense, unpleasant leg sensations, and an irresistible ... poor sleep and daytime drowsiness. It affects as many as ...
Cached Medicine News:Health News:Case Western Reserve receives prestigious $5.4 million grant to study esophageal cancer 2Health News:Case Western Reserve receives prestigious $5.4 million grant to study esophageal cancer 3Health News:Common medications can contribute to lower urinary tract symptoms in men 2Health News:ARRO honors 39 with Educator of the Year Award 2Health News:Herbal supplements may cause dangerous drug interactions in orthopaedic surgery patients 2Health News:Herbal supplements may cause dangerous drug interactions in orthopaedic surgery patients 3Health News:Men with disabilities 4 times more likely to be sexually abused than men without disabilities 2Health News:Restless legs syndrome may raise high blood pressure risk in middle-aged women 2
(Date:2/27/2015)... 2015  Acsis Inc., the market leader for supply ... that John DiPalo , Acsis, Chief Strategy Officer, ... Chain Executive 2015 Provider Pro to Know. The ... to help prepare their companies, and customers, supply chains ... year,s list of Provider Pros to Know is featured ...
(Date:2/27/2015)... Feb. 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... both its pro forma net operating loss (NOL) guidance ... strong financial position.  Isis, significantly improved financial results were ... million in payments the Company received from its partners.  ... was a nearly 60% improvement over its 2013 NOL ...
(Date:2/27/2015)... February 27, 2015 Report Details ... showing you trends, R&D progress, and predicted revenues ,Where ... What are the commercial prospects for this market and ... revenues and other trends to 2025, discussing data, opportunities ... you assess regenerative medicine : cell-based therapies that ...
Breaking Medicine Technology:Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... 2012  Boehringer Ingelheim will present results from LUX-Lung ... investigating afatinib in patients with stage IIIB or ... epidermal growth factor receptor (EGFR) mutation (EGFR M+), ... Society of Clinical Oncology (ASCO) in Chicago, June ...
... May 16, 2012  Leading events organiser UBM Conferences ... announced details of the forthcoming CPhI Extractables and Leachables ... 2pm IST/9:30am GMT/4:30pm CST. The free to attend webinar ... extractables and leachables and during drug development, in addition ...
Cached Medicine Technology:Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 2Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 3Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 4Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 5Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 6Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 7Global Webinar Focuses on Considerations for Extractables and Leachables 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: